These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 33764690)

  • 1. Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib.
    Nurwidya F; Takahashi F; Winardi W; Tajima K; Mitsuishi Y; Murakami A; Kobayashi I; Nara T; Hashimoto M; Kato M; Hidayat M; Suina K; Hayakawa D; Asao T; Ko R; Shukuya T; Yae T; Shimada N; Yoshioka Y; Sasaki S; Takahashi K
    Thorac Cancer; 2021 May; 12(10):1536-1548. PubMed ID: 33764690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
    Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
    Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
    Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
    Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
    Murakami A; Takahashi F; Nurwidya F; Kobayashi I; Minakata K; Hashimoto M; Nara T; Kato M; Tajima K; Shimada N; Iwakami S; Moriyama M; Moriyama H; Koizumi F; Takahashi K
    PLoS One; 2014; 9(1):e86459. PubMed ID: 24489728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
    Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
    Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Yoshida T; Song L; Bai Y; Kinose F; Li J; Ohaegbulam KC; Muñoz-Antonia T; Qu X; Eschrich S; Uramoto H; Tanaka F; Nasarre P; Gemmill RM; Roche J; Drabkin HA; Haura EB
    PLoS One; 2016; 11(1):e0147344. PubMed ID: 26789630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
    Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
    PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

  • 10. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells.
    Pérez G; López-Moncada F; Indo S; Torres MJ; Castellón EA; Contreras HR
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.
    Gohlke L; Alahdab A; Oberhofer A; Worf K; Holdenrieder S; Michaelis M; Cinatl J; Ritter CA
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas signaling induces stemness properties in colorectal cancer by regulation of Bmi1.
    Chen J; Wang Y; Zhuo L; Liu Z; Liu T; Li W; Cai Y; Zheng H
    Mol Carcinog; 2017 Oct; 56(10):2267-2278. PubMed ID: 28543447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnolol regulates miR-200c-3p to inhibit epithelial-mesenchymal transition and retinoblastoma progression by modulating the ZEB1/E-cadherin axis in vitro and in vivo.
    Lai YH; Liu WL; Lee TY; Kuo CW; Liu YR; Huang CY; Chen YH; Chen IL; Wu SH; Wang SC; Lee PY; Liu CC; Lo J; Chang YC; Kuo HF; Hsieh CC; Li CY; Liu PL
    Phytomedicine; 2023 Feb; 110():154597. PubMed ID: 36603340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer.
    Yuan W; Ji J; Shu Y; Chen J; Liu S; Wu L; Zhou Z; Liu Z; Tang Q; Zhang X; Shu X
    J Mol Med (Berl); 2019 Jan; 97(1):89-102. PubMed ID: 30460377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genetic cell context-dependent role for ZEB1 in lung cancer.
    Zhang T; Guo L; Creighton CJ; Lu Q; Gibbons DL; Yi ES; Deng B; Molina JR; Sun Z; Yang P; Yang Y
    Nat Commun; 2016 Jul; 7():12231. PubMed ID: 27456471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation.
    Li Y; Wang L; Pappan L; Galliher-Beckley A; Shi J
    Mol Cancer; 2012 Nov; 11():87. PubMed ID: 23174018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
    Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
    Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.